1
Clinical Trials associated with CD19-STAR-T cell therapy(China Immunotech Co., Ltd.)CD19-STAR-T for Patients With B Cell Malignancies
This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of CD19-STAR-T cells in patients with refractory and relapsed B-cell malignancies (such as NHL and ALL ).
100 Clinical Results associated with CD19-STAR-T cell therapy(China Immunotech Co., Ltd.)
100 Translational Medicine associated with CD19-STAR-T cell therapy(China Immunotech Co., Ltd.)
100 Patents (Medical) associated with CD19-STAR-T cell therapy(China Immunotech Co., Ltd.)
100 Deals associated with CD19-STAR-T cell therapy(China Immunotech Co., Ltd.)